Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9

被引:9
作者
Amiri, Maryam [1 ]
Moaveni, Amir Kian [1 ]
Zolbin, Masoumeh Majidi [1 ]
Shademan, Behrouz [2 ]
Nourazarian, Alireza [3 ]
机构
[1] Univ Tehran Med Sci, Pediat Urol & Regenerat Med Res Ctr, Childrens Med Ctr, Tehran, Iran
[2] Shiraz Univ Med Sci, Sch Paramed Sci, Med Journalism, Shiraz, Iran
[3] Khoy Univ Med Sci, Dept Basic Med Sci, Khoy, Iran
关键词
CAR-T cell therapy; CRISPR/Cas9; technology; immunotherapy; genetic engineering; personalized cancer treatment; CHIMERIC-ANTIGEN-RECEPTOR; HOMOLOGY-DIRECTED REPAIR; CRISPR-CAS9; CAS9; TARGET; SPECIFICITY; GENERATION; MALIGNANCY; LEUKEMIA; EFFICACY;
D O I
10.3389/fimmu.2024.1462697
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Optimizing cancer treatment has become a pivotal goal in modern oncology, with advancements in immunotherapy and genetic engineering offering promising avenues. CAR-T cell therapy, a revolutionary approach that harnesses the body's own immune cells to target and destroy cancer cells, has shown remarkable success, particularly in treating acute lymphoblastic leukemia (ALL), and in treating other hematologic malignancies. While CAR-T cell therapy has shown promise, challenges such as high cost and manufacturing complexity remain. However, its efficacy in solid tumors remains limited. The integration of CRISPR/Cas9 technology, a powerful and precise genome-editing tool, also raises safety concerns regarding unintended edits and off-target effects, offers a synergistic potential to overcome these limitations. CRISPR/Cas9 can enhance CAR-T cell therapy by improving the specificity and persistence of CAR-T cells, reducing off-target effects, and engineering resistance to tumor-induced immunosuppression. This combination can also facilitate the knockout of immune checkpoint inhibitors, boosting the anti-tumor activity of CAR-T cells. Recent studies have demonstrated that CRISPR/Cas9-edited CAR-T cells can target previously untreatable cancer types, offering new hope for patients with refractory cancers. This synergistic approach not only enhances the efficacy of cancer treatment but also paves the way for personalized therapies tailored to individual genetic profiles. This review highlights the ongoing research efforts to refine this approach and explores its potential to revolutionize cancer treatment across a broader range of malignancies. As research progresses, the integration of CAR-T cell therapy and CRISPR/Cas9 holds the promise of transforming cancer treatment, making it more effective and accessible. This review explores the current advancements, challenges, and future prospects of this innovative therapeutic strategy.
引用
收藏
页数:18
相关论文
共 152 条
[81]   Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining [J].
Maruyama, Takeshi ;
Dougan, Stephanie K. ;
Truttmann, Matthias C. ;
Bilate, Angelina M. ;
Ingram, Jessica R. ;
Ploegh, Hidde L. .
NATURE BIOTECHNOLOGY, 2015, 33 (05) :538-U260
[82]   Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia [J].
Maude, S. L. ;
Laetsch, T. W. ;
Buechner, J. ;
Rives, S. ;
Boyer, M. ;
Bittencourt, H. ;
Bader, P. ;
Verneris, M. R. ;
Stefanski, H. E. ;
Myers, G. D. ;
Qayed, M. ;
De Moerloose, B. ;
Hiramatsu, H. ;
Schlis, K. ;
Davis, K. L. ;
Martin, P. L. ;
Nemecek, E. R. ;
Yanik, G. A. ;
Peters, C. ;
Baruchel, A. ;
Boissel, N. ;
Mechinaud, F. ;
Balduzzi, A. ;
Krueger, J. ;
June, C. H. ;
Levine, B. L. ;
Wood, P. ;
Taran, T. ;
Leung, M. ;
Mueller, K. T. ;
Zhang, Y. ;
Sen, K. ;
Lebwohl, D. ;
Pulsipher, M. A. ;
Grupp, S. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05) :439-448
[83]   Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia [J].
Maude, Shannon L. ;
Frey, Noelle ;
Shaw, Pamela A. ;
Aplenc, Richard ;
Barrett, David M. ;
Bunin, Nancy J. ;
Chew, Anne ;
Gonzalez, Vanessa E. ;
Zheng, Zhaohui ;
Lacey, Simon F. ;
Mahnke, Yolanda D. ;
Melenhorst, Jan J. ;
Rheingold, Susan R. ;
Shen, Angela ;
Teachey, David T. ;
Levine, Bruce L. ;
June, Carl H. ;
Porter, David L. ;
Grupp, Stephan A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16) :1507-1517
[84]   T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans [J].
Maus, Marcela V. ;
Haas, Andrew R. ;
Beatty, Gregory L. ;
Albelda, Steven M. ;
Levine, Bruce L. ;
Liu, Xiaojun ;
Zhao, Yangbing ;
Kalos, Michael ;
June, Carl H. .
CANCER IMMUNOLOGY RESEARCH, 2013, 1 (01) :26-31
[85]   Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells [J].
Meyers, Robin M. ;
Bryan, Jordan G. ;
McFarland, James M. ;
Weir, Barbara A. ;
Sizemore, Ann E. ;
Xu, Han ;
Dharia, Neekesh V. ;
Montgomery, Phillip G. ;
Cowley, Glenn S. ;
Pantel, Sasha ;
Goodale, Amy ;
Lee, Yenarae ;
Ali, Levi D. ;
Jiang, Guozhi ;
Lubonja, Rakela ;
Harrington, William F. ;
Strickland, Matthew ;
Wu, Ting ;
Hawes, Derek C. ;
Zhivich, Victor A. ;
Wyatt, Meghan R. ;
Kalani, Zohra ;
Chang, Jaime J. ;
Okamoto, Michael ;
Stegmaier, Kimberly ;
Golub, Todd R. ;
Boehm, Jesse S. ;
Vazquez, Francisca ;
Root, David E. ;
Hahn, William C. ;
Tsherniak, Aviad .
NATURE GENETICS, 2017, 49 (12) :1779-+
[86]   Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors [J].
Miao, Lele ;
Zhang, Zhengchao ;
Ren, Zhijian ;
Tang, Futian ;
Li, Yumin .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[87]   Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 [J].
Morgan, Richard A. ;
Yang, James C. ;
Kitano, Mio ;
Dudley, Mark E. ;
Laurencot, Carolyn M. ;
Rosenberg, Steven A. .
MOLECULAR THERAPY, 2010, 18 (04) :843-851
[88]   Chimeric antigen receptor T-cell therapy - assessment and management of toxicities [J].
Neelapu, Sattva S. ;
Tummala, Sudhakar ;
Kebriaei, Partow ;
Wierda, William ;
Gutierrez, Cristina ;
Locke, Frederick L. ;
Komanduri, Krishna V. ;
Lin, Yi ;
Jain, Nitin ;
Daver, Naval ;
Westin, Jason ;
Gulbis, Alison M. ;
Loghin, Monica E. ;
de Groot, John F. ;
Adkins, Sherry ;
Davis, Suzanne E. ;
Rezvani, Katayoun ;
Hwu, Patrick ;
Shpall, Elizabeth J. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) :47-62
[89]   USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination [J].
Novellasdemunt, Laura ;
Foglizzo, Valentina ;
Cuadrado, Laura ;
Antas, Pedro ;
Kucharska, Anna ;
Encheva, Vesela ;
Snijders, Ambrosius P. ;
Li, Vivian S. W. .
CELL REPORTS, 2017, 21 (03) :612-627
[90]   A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry [J].
Olejniczak, SH ;
Stewart, CC ;
Donohue, K ;
Czuczman, MS .
IMMUNOLOGICAL INVESTIGATIONS, 2006, 35 (01) :93-114